For investors in Singapore

Andy Acker, CFA

Global Life Sciences | Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 27 years of financial industry experience.

Download hi-res headshot

Articles Written

Healthcare stocks show signs of strength
Timely & Topical

Healthcare stocks show signs of strength

Andy Acker discusses how pricing power, growing demand, and an improving outlook for biotech could bolster the sector heading into 2023.

Signs of recovery in biotech?
Timely & Topical

Signs of recovery in biotech?

Low valuations, positive clinical trial data and clarity around drug pricing reform could help revive the sector’s beaten-down stocks.

Exploring the science – and business – of biotech
Features & Outlooks

Exploring the science – and business – of biotech

A discussion on potential investment opportunities in health care despite a record sell-off in small- and mid-cap biotech stocks.

Health care strikes a balance
Features & Outlooks

Health care strikes a balance

Why health care could be well positioned to offer both defense against market volatility and opportunities for long-term growth.

Making sense of drug pricing reform for investors
Timely & Topical

Making sense of drug pricing reform for investors

Why we believe the biopharma industry should be able to adapt to drug pricing changes.

Health care’s recession playbook

Health care’s recession playbook

Some areas of health care benefit from steady demand and the ability to pass on price increases – appealing qualities amid slowing economic growth.

How weight loss could yield gains for investors

How weight loss could yield gains for investors

A breakthrough in anti-obesity medication could help millions of people struggling with excess weight and create a new growth opportunity for health care investors.

Amid volatility, healthcare’s appeal grows

Amid volatility, healthcare’s appeal grows

What are the opportunities in the healthcare sector in today’s uncertain financial markets?

Can Biotech Bounce Back?
Features & Outlooks

Can Biotech Bounce Back?

For more than a year, biotechnology stocks have been deep in the red, even as medical breakthroughs continue – a disconnect we think is unlikely to last.

From defense to offense in biotech

From defense to offense in biotech

Why the beaten-down sector may be worth another look.

Opportunities in healthcare in 2022

Opportunities in healthcare in 2022

COVID-19 has had an outsize influence on healthcare stocks. With the pandemic hopefully retreating, what’s next for the sector?

Drug pricing reform shifts continue

Drug pricing reform shifts continue

Recently, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But US drug reform is far from over, with implications for investors, says Portfolio Manager Andy Acker and Health Care Research Analysts Luyi Guo and Rich Carney. The road to